These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 37108398)

  • 1. Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA.
    Szczepanek J; Skorupa M; Jarkiewicz-Tretyn J; Cybulski C; Tretyn A
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
    Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
    Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetics of Breast Cancer: Clinical Status of Epi-drugs and Phytochemicals.
    Shukla S; Penta D; Mondal P; Meeran SM
    Adv Exp Med Biol; 2019; 1152():293-310. PubMed ID: 31456191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond regulations at DNA levels: A review of epigenetic therapeutics targeting cancer stem cells.
    Zhang S; Gong Y; Li C; Yang W; Li L
    Cell Prolif; 2021 Feb; 54(2):e12963. PubMed ID: 33314500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of epigenetic drugs in sensitizing cancers to anticancer therapies: emerging trends and clinical advancements.
    Singh D; Khan MA; Siddique HR
    Epigenomics; 2023 Apr; 15(8):517-537. PubMed ID: 37313832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic therapies in patients with solid tumors: Focus on monotherapy with deoxyribonucleic acid methyltransferase inhibitors and histone deacetylase inhibitors.
    Katarzyna R; Lucyna B
    J Cancer Res Ther; 2019; 15(5):961-970. PubMed ID: 31603095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting miRNAs by histone deacetylase inhibitors (HDACi): Rationalizing epigenetics-based therapies for breast cancer.
    Ediriweera MK; Cho SK
    Pharmacol Ther; 2020 Feb; 206():107437. PubMed ID: 31715287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetics in Metastatic Breast Cancer: Its Regulation and Implications in Diagnosis, Prognosis and Therapeutics.
    Wu YS; Lee ZY; Chuah LH; Mai CW; Ngai SC
    Curr Cancer Drug Targets; 2019; 19(2):82-100. PubMed ID: 29714144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic Modulations in Breast Cancer: An Emerging Paradigm in Therapeutic Implications.
    Sarkar S; Venkatesh D; Kandasamy T; Ghosh SS
    Front Biosci (Landmark Ed); 2024 Aug; 29(8):287. PubMed ID: 39206915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.
    Su Y; Hopfinger NR; Nguyen TD; Pogash TJ; Santucci-Pereira J; Russo J
    J Exp Clin Cancer Res; 2018 Dec; 37(1):314. PubMed ID: 30547810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic Regulation in Breast Cancer.
    Nam HJ; Baek SH
    Adv Exp Med Biol; 2021; 1187():103-119. PubMed ID: 33983575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.
    Ali SR; Humphreys KJ; McKinnon RA; Michael MZ
    Drug Dev Res; 2015 Sep; 76(6):296-317. PubMed ID: 26303212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic therapy for breast cancer.
    Cai FF; Kohler C; Zhang B; Wang MH; Chen WJ; Zhong XY
    Int J Mol Sci; 2011; 12(7):4465-87. PubMed ID: 21845090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic modifications in prostate cancer.
    Ngollo M; Dagdemir A; Karsli-Ceppioglu S; Judes G; Pajon A; Penault-Llorca F; Boiteux JP; Bignon YJ; Guy L; Bernard-Gallon DJ
    Epigenomics; 2014; 6(4):415-26. PubMed ID: 25333850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer.
    Oh S; Ko JY; Oh C; Yoo KH
    Adv Exp Med Biol; 2017; 1026():287-313. PubMed ID: 29282690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic Modulators as Therapeutic Agents in Cancer.
    Patnaik E; Madu C; Lu Y
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors.
    Teixeira SR; Abreu CM; Parkes L; Davies J; Yao S; Sawhney MA; Margarit L; Gonzalez D; Pinto IM; Francis LW; Conlan RS
    Biosens Bioelectron; 2019 Sep; 141():111386. PubMed ID: 31220725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic targeting in breast cancer: therapeutic impact and future direction.
    Lustberg MB; Ramaswamy B
    Drug News Perspect; 2009 Sep; 22(7):369-81. PubMed ID: 19890494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
    Vijayaraghavalu S; Dermawan JK; Cheriyath V; Labhasetwar V
    Mol Pharm; 2013 Jan; 10(1):337-52. PubMed ID: 23215027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetics as a therapeutic target in breast cancer.
    Connolly R; Stearns V
    J Mammary Gland Biol Neoplasia; 2012 Dec; 17(3-4):191-204. PubMed ID: 22836913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.